{"product_id":"lirilumab-elisa-kit-bhe21400268","title":"Lirilumab ELISA Kit","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eLirilumab ELISA Kit\u003c\/strong\u003e is an ELISA-based immunoassay designed for quantitative measurement of \u003cstrong\u003eLirilumab\u003c\/strong\u003e in research samples. It is commonly used to generate traceable concentration data for biomarker discovery, pathway studies, and comparative analyses across experimental conditions.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAssay format:\u003c\/strong\u003e Quantitative Colorimetric ELISA. The format defines how signal scales with analyte abundance and how results are interpreted across a standard curve.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWorking range and sensitivity:\u003c\/strong\u003e dynamic range 0.31-5 μg\/mL; analytical sensitivity 0.156 μg\/ml. Use these values to plan dilutions and keep readouts within the linear portion of the calibration curve.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSample compatibility:\u003c\/strong\u003e Intended for Plasma, Serum matrices. As with most immunoassays, matrix composition can influence apparent signal and should be evaluated with dilution linearity and spike-recovery concepts.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRecovery reference:\u003c\/strong\u003e Typical recovery is reported as 80-120%. Recovery helps assess whether the sample matrix interferes with detection of spiked analyte.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eThis kit is supplied for research use in laboratory settings where defined, quantitative readouts are needed for experimental interpretation.\u003c\/p\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003eLirilumab (IPH2102\/BMS-986015\/BMS-986015-01) is a fully human monoclonal antibody (mAb) that is designed to block the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands. This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb. A phase 2 clinical trial for acute myeloid leukemia (AML) was terminated early (\"failed\") in 2017. It was registered for a trial for squamous cell carcinoma of the head and neck (SCCHN), but it may be abandoned. On 22 May 2018, a clinical trial for Bladder Cancer was started by PrECOG LLC.\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiomarker translation in RUO settings:\u003c\/strong\u003e Increasing use of quantitative immunoassays to stratify experimental cohorts, track longitudinal changes, and benchmark model systems.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMatrix-aware assay design:\u003c\/strong\u003e Greater emphasis on dilution linearity, spike-recovery, and control concepts to reduce matrix-driven artifacts in serum\/plasma and complex lysates.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIntegration with multi-omics:\u003c\/strong\u003e ELISA measurements are often used alongside transcriptomics and proteomics to connect abundance changes with pathway activity and phenotype.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eComparative quantification:\u003c\/strong\u003e Measure relative changes in analyte levels across treatments, time points, or genotypes to support mechanistic hypotheses.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAssay development and standardization:\u003c\/strong\u003e Generate reproducible concentration inputs for method qualification, inter-operator comparisons, or bridging studies across platforms.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eModel and sample characterization:\u003c\/strong\u003e Profile baseline and stimulated levels to help interpret immune, endocrine, neurodegenerative, or metabolic phenotypes (as relevant to the target).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eInterpretation typically focuses on direction and magnitude of change in the context of controls and sample handling metadata, rather than single-point absolute values.\u003c\/p\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMatrix effects:\u003c\/strong\u003e Hemolysis, lipemia, and high protein content can alter background and apparent concentration. Consider consistent collection\/processing and evaluate dilution behavior.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsoforms and modified forms:\u003c\/strong\u003e Some targets exist as isoforms, fragments, or post-translationally modified species. Ensure the measured form aligns with the biological question and the kit’s intended analyte definition.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e Use negative\/blank controls, replicate wells, and—when feasible—orthogonal confirmation (e.g., WB or MS) to strengthen conclusions.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c!-- Sources (internal): - UniProt (search): https:\/\/www.uniprot.org\/uniprotkb?query=Lirilumab - NCBI Gene (search): https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=Lirilumab - Ensembl (search): https:\/\/www.ensembl.org\/Multi\/Search\/Results?q=Lirilumab - PubMed (search): https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Lirilumab - NCBI Bookshelf (background reviews): https:\/\/www.ncbi.nlm.nih.gov\/books\/?term=Lirilumab --\u003e","brand":"Biohippo Inc","offers":[{"title":"96 T","offer_id":53047352721773,"sku":"DW759018-96T","price":1126.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/ELISA_Kits_Display_Image_1_9b332bef-02a8-4e93-a53a-dcc87bea326e.png?v=1772020760","url":"https:\/\/www.ebiohippo.com\/products\/lirilumab-elisa-kit-bhe21400268","provider":"BioHippo","version":"1.0","type":"link"}